Stockscreener 앱 받기
4.38
0.46%
0.02
시간 외 거래:
4.34
-0.04
-0.91%
Cel-Sci Corp. 주식(CVM)의 최신 뉴스
Insider Sell: Does CEL SCI Corporation stock have upside surprise potential2026 Trade Ideas & Safe Entry Point Identification - baoquankhu1.vn
INMB.O PE Ratio & Valuation, Is INMB.O Overvalued - Intellectia AI
XCUR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
CVM Technical Analysis & Stock Price Forecast - Intellectia AI
[Form 4] CEL SCI CORP Insider Trading Activity - Stock Titan
CEL-SCI (CVM) CFO awarded 1,336 Common Stock shares in Form 4 filing - Stock Titan
CEL SCI (CVM) CEO awarded 1,682 shares of common stock - Stock Titan
CEO Moves: Is CEL SCI Corporation stock undervalued right nowTrade Risk Summary & Weekly High Momentum Picks - baoquankhu1.vn
If You Invested $1,000 in Adicet Bio Inc (ACET) - Stock Titan
If You Invested $1,000 in CEL-SCI Corp (CVM) - Stock Titan
Trading Action: Is CEL SCI Corporation a strong candidate for buy and hold2026 Snapshot & Entry Point Confirmation Signals - baoquankhu1.vn
Why did CVM shares rally over 7% today? - MSN
CVM PE Ratio & Valuation, Is CVM Overvalued - Intellectia AI
CEL-SCI's Multikine Therapy Nears Critical Regulatory Milestones () - aktiencheck.de
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Volume Recap: Is Regencell Bioscience Holdings Limited stock a smart retirement pickJuly 2025 Macro Moves & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Why DID CVM Shares Rally Over 7% Today? - Stocktwits
Cel-Sci (CVM) Reports Narrower Q1 Net Loss - GuruFocus
CEL-SCI Reports Fiscal First Quarter 2026 Results - Investing News Network
Cancer therapy lifted 5-year survival to 73% in trial; next test in 2026 - Stock Titan
Cel-Sci: Fiscal Q1 Earnings Snapshot - kens5.com
Cel-Sci: Overview of First Fiscal Quarter Financial Results - Bitget
CEL SCI CORP SEC 10-Q Report - TradingView
Big Money Moves: Does CEL SCI Corporation stock have upside surprise potential - baoquankhu1.vn
Investment Review: Is CEL SCI Corporation trading at a discountJuly 2025 Snapshot & Comprehensive Market Scan Reports - baoquankhu1.vn
IPO Launch: Is CEL SCI Corporation trading at a discountWeekly Trading Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Cel-Sci (NYSEAMERICAN:CVM) Stock Price Down 6.9% – Should You Sell? - Defense World
Kersten Geert buys Cel Sci (CVM) shares worth $200000 By Investing.com - Investing.com Australia
Insider Buying: Geert Kersten Acquires Additional Shares of CEL-SCI Corp (CVM) - GuruFocus
Kersten Geert buys Cel Sci (CVM) shares worth $200000 - Investing.com
Profit Recap: Does CEL SCI Corporation stock have upside surprise potentialWeekly Investment Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Cel Sci (CVM) Options Delisting Set for January 20th - GuruFocus
Surprises Report: Why CEL SCI Corporation stock could outperform in 2025M&A Rumor & AI Enhanced Trading Alerts - Bộ Nội Vụ
Cel-Sci (NYSEAMERICAN:CVM) Stock Price Down 6.5% – What’s Next? - Defense World
Cel-Sci Corporation (CVM) Investor Outlook: Exploring A Potential 625% Upside - DirectorsTalk Interviews
Is CEL SCI Corporation stock dividend yield sustainable2025 Geopolitical Influence & Long-Term Safe Investment Ideas - Улправда
Is CEL SCI Corporation stock positioned well for digital economyJuly 2025 Selloffs & Expert Curated Trade Setup Alerts - Улправда
Is CEL SCI Corporation stock a contrarian buyPortfolio Performance Summary & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
Cel-sci-sci Corp : Dutton Associates Announces Investment Opinion - marketscreener.com
CEL-SCI (CVM) Chief Scientific Officer reports purchase of 456 shares - Stock Titan
CEL-SCI (CVM) CFO Patricia Prichep reports insider stock purchase - Stock Titan
CEL-SCI Corp (CVM) CEO and Director reports purchase of 998 shares - Stock Titan
Cel-Sci Corporation (CVM) Stock Analysis: Exploring a Potential 707% Upside with Innovative Cancer Therapies - DirectorsTalk Interviews
Cel-Sci (CVM) Reduces R&D Costs and Narrows Net Loss in FY 2025 - GuruFocus
Cancer drug Multikine nears final U.S. trial, seeks Saudi breakthrough status - Stock Titan
CEL SCI CORP SEC 10-K Report - TradingView — Track All Markets
CEL-SCI (NYSE American: CVM) details Multikine survival data and cash outlook - Stock Titan
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Why CEL SCI Corporation stock is rated strong buyWeekly Risk Report & Safe Swing Trade Setups - Улправда
2.69%
0.25%
자본화:
|
볼륨(24시간):